CIK 1560009
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 100.00% | 8 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | GLUE | Monte Rosa Therapeutics, Inc. | Health Care | 37.00% |
| 2 | IPSC | Century Therapeutics, Inc. | Health Care | 19.44% |
| 3 | LENZ | LENZ Therapeutics, Inc. | Health Care | 17.19% |
| 4 | JBIO | Jade Biosciences, Inc. | Health Care | 15.16% |
| 5 | CTNM | Contineum Therapeutics, Inc. | Health Care | 5.01% |
| 6 | CRSP | CRISPR Therapeutics AG | Health Care | 5.01% |
| 7 | SKYE | Skye Bioscience, Inc. | Health Care | 0.87% |
| 8 | TPST | Tempest Therapeutics, Inc. | Health Care | 0.31% |
8/8 names classified · sector 100.0% of weight · industry 100.0% · mkt cap 100.0%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 100.0% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (0/8 names) · unclassified 100.0%: GLUE, IPSC, LENZ, JBIO, CTNM, CRSP, SKYE, TPST. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | GLUEMONTE ROSA THERAPEUTICS INC | 3,180,780 | $52M | 37.0% | TRIM −27% |
| 2 | IPSCCENTURY THERAPEUTICS INC | 12,166,109 | $27M | 19.4% | NEW |
| 3 | LENZLENZ THERAPEUTICS INC | 2,656,888 | $24M | 17.2% | HOLD |
| 4 | JBIOJADE BIOSCIENCES INC | 1,525,820 | $21M | 15.2% | HOLD |
| 5 | CTNMCONTINEUM THERAPEUTICS INC | 542,628 | $7M | 5.0% | HOLD |
| 6 | CRSPCRISPR THERAPEUTICS AG | 148,831 | $7M | 5.0% | HOLD |
| 7 | SKYESKYE BIOSCIENCE INC | 2,007,704 | $1M | 0.9% | HOLD |
| 8 | TPSTTempest Therapeutics, Inc. | 269,772 | $442,426 | 0.3% | HOLD |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| GLUEMONTE ROSA THERAPEUTICS INC | 5.7M | 5.7M | 5.7M | 5.7M | 4.4M | 3.2M | $52M |
| IPSCCENTURY THERAPEUTICS INC | — | — | — | — | — | 12.2M | $27M |
| LENZLENZ THERAPEUTICS INC | — | — | — | 2.7M | 2.7M | 2.7M | $24M |
| JBIOJADE BIOSCIENCES INC | — | — | 1.5M | 1.5M | 1.5M | 1.5M | $21M |
| CTNMCONTINEUM THERAPEUTICS INC | 918K | 918K | 543K | 543K | 543K | 543K | $7M |
| CRSPCRISPR THERAPEUTICS AG | 499K | 499K | 499K | 149K | 149K | 149K | $7M |
| SKYESKYE BIOSCIENCE INC | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | $1M |
| TPSTTempest Therapeutics, Inc. | 3.5M | — | 270K | 270K | 270K | 270K | $442,426 |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
